Gyre Therapeutics (NASDAQ:GYRE) Posts Earnings Results

Gyre Therapeutics (NASDAQ:GYRE) announced its quarterly earnings data on Thursday. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.19, Zacks reports. The company had revenue of $32.93 million during the quarter, compared to analysts’ expectations of $28.40 million. Gyre Therapeutics had a negative net margin of 15.47% and a negative return on equity of 6.57%.

Gyre Therapeutics Stock Up 18.7%

Shares of Gyre Therapeutics stock traded up $0.75 during trading hours on Friday, hitting $4.76. The company’s stock had a trading volume of 359,716 shares, compared to its average volume of 149,986. Gyre Therapeutics has a 1-year low of $3.97 and a 1-year high of $9.14. The business has a fifty day moving average of $6.51 and a 200 day moving average of $6.90. The company has a market capitalization of $530.79 million, a PE ratio of -23.80 and a beta of 2.14.

Wall Street Analyst Weigh In

Several equities research analysts have commented on GYRE shares. Wall Street Zen upgraded Gyre Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a research note on Wednesday. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.